Archives: Contractor Email

Dear Colleague

This is the second update of concessionary prices granted for December 2020.

DrugPack
Size		Concessionary
Price
Ciprofloxacin 500mg tablets10£3.30
Desmopressin 10micrograms/dose nasal spray60 dose£22.81
Docusate 12.5mg/5ml oral solution sugar free300ml£13.19
Docusate 50mg/5ml oral solution sugar free300ml£13.39
Docusate 100mg capsules30£3.20
Entacapone 200mg tablets30£8.12
Eplerenone 25mg tablets28£8.20
Eplerenone 50mg tablets28£7.79
Esomeprazole 40mg gastro-resistant capsules28£3.01
Esomeprazole 20mg gastro-resistant tablets28£5.58
Lamotrigine 200mg tablets56£5.08
Olmesartan medoxomil 10mg tablets28£3.09
Olmesartan medoxomil 40mg tablets28£3.79
Sulfasalazine 500mg gastro-resistant tablets112£11.95
Sulfasalazine 500mg tablets112£7.20
Trimethoprim 100mg tablets28£2.07
Zonisamide 100mg capsules56£61.16

Concessionary prices will be paid against the usual code, no additional endorsements are needed.
 
Concessionary prices may be granted up until the end of the month so CPNI will notify you of any further concessionary prices as and when they are agreed.
 
Please continue to notify CPNI of any pricing issues you are experiencing via our new Medicine Shortage Reporter

https://www.communitypharmacyni.co.uk/item-shortages/
 
Concessionary prices are also published on the CPNI website

https://www.communitypharmacyni.co.uk/services/concessionary-prices/

Yours sincerely

SENT ON BEHALF OF DR. GARETH C. GILVARY | Governance & Support Pharmacist

Dear Contractor

Please see correspondence below from Joe Brogan, Assistant Director of Integrated Care, Head of Pharmacy and Medicines Management.

Letter

Appendix I Template

SUMMARY

Accord-UK Ltd has announced that all strengths of their branded modified release gliclazide tablets, Bilxona® have been discontinued. This is a commercial decision made by the pharmaceutical company.

ACTION REQUIRED

The discontinuation of this brand will require prescriptions for Bilxona® to be changed to gliclazide MR.                                                                         Identify patients currently being prescribed Bilxona® in order for their prescriptions to be changed. A template letter for patients to support the prescribing changes is included within the correspondence.

If you require further information, please contact your local HSCB Pharmacy Adviser.

Yours sincerely

Vanessa

SENT ON BEHALF OF DR. VANESSA CHAMBERS | Head of Policy & Development

Dear Contractor

Please see correspondence below from Joe Brogan, Assistant Director of Integrated Care, Head of Pharmacy and Medicines Management.

SUMMARY

Accord-UK Ltd has announced that all strengths of their branded modified release gliclazide tablets, Bilxona® have been discontinued. This is a commercial decision made by the pharmaceutical company.

ACTION REQUIRED

  • The discontinuation of this brand will require prescriptions for Bilxona® to be changed to Gliclazide MR.                                                                        
  • Identify patients currently being prescribed Bilxona® in order for their prescriptions to be changed. A template letter for patients to support the prescribing changes is included within the correspondence.

If you require further information, please contact your local HSCB Pharmacy Adviser.

Yours sincerely

Vanessa

SENT ON BEHALF OF DR. VANESSA CHAMBERS | Head of Policy & Development

Dear Contractor

The Department of Health has written to contractors clarifying the position in respect of prescriptions issued by EEA Health Professionals following the end of the transition period on 31 December 2020 (letter here).

Action

Contractors are advised to:

  • Note the content of the letter and advise their dispensary teams accordingly.

Colleagues in CPNI will continue to update you on these matters as EU Exit progresses.

Yours sincerely

Mike

Sent on behalf of Prof Mike Mawhinney | Head of Regulatory Affairs

Dear Contractor

You will be aware that import declarations will be required for goods moving from Great Britain (GB) to Northern Ireland (NI) from 1 January 2021. These include medicines, medical devices and medical consumables.
 
In relation to registering with the Trader Support Service (TSS) and obtaining an XI EORI, the CPO has written to contractors providing details of a webinar dedicated to the healthcare sector in respect of these matters (letter here).

Action

Contractors are advised to note:

Colleagues in CPNI will continue to support you during the EU Exit process.

Yours sincerely

Mike

Sent on behalf of Prof Mike Mawhinney | Head of Regulatory Affairs

Dear Colleague

Please see correspondence here for your attention, from Dr Michael McBride, Chief Medical Officer and Cathy Harrison, Chief Pharmaceutical Officer.

Yours sincerely

SENT ON BEHALF OF GERARD GREENE | Chief Executive